Edible Garden Regains Nasdaq Compliance
The company received formal confirmation from Nasdaq that it is in compliance with minimum bid price requirements after a compliance period. This regaining of compliance ensures th…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
The company received formal confirmation from Nasdaq that it is in compliance with minimum bid price requirements after a compliance period. This regaining of compliance ensures th…
uniQure submitted a Biologics License Application to the FDA and a Marketing Authorisation Application to the MHRA for AMT-130, seeking accelerated approval for Huntington's diseas…
Alaska's AIDEA authorized significant funding for the geotechnical and engineering work required to build a state-led access road connecting the Whistler gold project to Anchorage.…
IP Strategy Holdings received notification from Nasdaq for delayed fiscal 2026 Form 10-Q filing. The company plans to regain compliance in September to avoid potential delisting.
Mid Penn Bancorp filed an 8-K to amend its bylaws with the SEC as of August 26, 2026.
Hornbeck Offshore Services, Inc. filed an SEC 8-K containing Exhibit 3.1, a Certificate of Incorporation for a different entity called Helix Energy Solutions Group, Inc. This appea…
C-IV Asset Management selected Greystone Servicing Company as the special servicer for a mortgage loan, effective September 1, 2026. This change of servicer may impact future colle…
Royale Energy has filed delinquent reports and resumed OTC Pink trading. The company has initiated an application process to be added to the OTCQB Venture Market. Trading has resum…
Montis CPA limited, an independent auditor, issued a signed letter confirming they agree with IT Tech Packaging's disclosure under Item 4.01 of its Form 8-K.
Alumis CEO Jörg Drappa announces that the Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus did not meet primary endpoints in the overall population; however,…
Upstream Bio, Inc. has announced pivotal Phase 3 development plans for its TSLP antagonist verekitug in severe asthma and CRSwNP. The company aims to initiate both trials in Q1 202…
Adicet Bio reported the completion of a key SLE study for prula-cel, with topline data expected in September 2026. The company also announced FDA clearance for its ADI-212 mCRPC pr…
Geotech drilling is underway for the West Susitna Access Road, linking Nova's Estelle Project to a planned refinery. AIDEA authorized the additional $25 million to finish fieldwork…
XTI Aerospace received a deficiency notice from Nasdaq for failing to file its Q3 2026 Form 10-Q on time due to an ongoing internal review of its former CEO. The company has 60 day…
The company views the federal government's policy shift as a significant evolution in cannabinoid regulation, which could remove legal barriers to research. Endovia plans to submit…
BridgeBio Pharma entered a voluntary agreement with the U.S. Administration to expand Medicaid access to its medicine without future pricing mandates, sustaining innovation. The an…
MicroVision has regained compliance after its stock bid price recovered above $1. The situation is now closed, allowing the company to focus on its commercial strategy.
Following a 1-for-4 reverse stock split, Nasdaq initially deemed Profusa non-compliant with the $500,000 publicly held shares minimum requirement. However, a subsequent amendment c…
Cadrenal Therapeutics announced FDA alignment on the primary endpoint and trial design for CAD-1005, a first-in-class therapy for heparin-induced thrombocytopenia. The agreement po…
Ocean Capital Acquisition Corp's accounting firm issued a confirmation letter regarding the firm's identity and agreement with an 8-K disclosure entry.